AstraZeneca has become one of the dominant forces in cancer drug development. A lot of the credit goes to Susan Galbraith, who since joining the company in 2010 has played a key role in picking which drugs to advance and emerged as one of the most prominent women in the pharmaceutical industry. Among AstraZeneca’s most recent oncology advances: “extraordinary” survival rates among patients with non-small cell lung cancer who took its drug Tagrisso after having their tumors removed, and promising results in a late-stage trial that showed its experimental drug slowed the progression of one type of breast cancer.
Industry
Location
-
Cambridge, England
